SWX:DKSH
SWX:DKSHTrade Distributors

Will SBTi-Validated Net-Zero Targets Redefine DKSH Holding's (SWX:DKSH) Long-Term Resilience Narrative?

DKSH Holding AG recently received official validation from the Science Based Targets initiative that its near-term and net-zero emissions targets align with climate science and the Paris Agreement, confirming deep reductions in Scope 1, 2, and 3 emissions and a commitment to net-zero across its value chain by 2050. This independent endorsement strengthens DKSH’s sustainability positioning, underscoring how its efforts in transport optimization, renewable electricity, fleet electrification,...
SWX:UBSG
SWX:UBSGCapital Markets

How Investors Are Reacting To UBS Group (SWX:UBSG) Challenging Tighter Capital Rules After New Bond Issues

Earlier this month, UBS Group AG completed two US$1.50 billion fixed-coupon, perpetual, callable subordinated Eurobond issues, while simultaneously intensifying its public opposition to proposed tighter Swiss banking capital rules following the Credit Suisse collapse. By arguing that fully capitalizing foreign subsidiaries and raising capital buffers could add about US$1.70 billion in annual costs and threaten its business model, UBS has put the trade-off between financial stability and...
SWX:TECN
SWX:TECNLife Sciences

Tecan Group (SWX:TECN) Posts Flat H2 Local-Currency Sales Is Its Recovery Story Credible?

Tecan Group AG has released unaudited preliminary results for fiscal 2025, reporting second-half sales growth of 0.4% in local currencies but a 5.2% decline in Swiss francs to CHF 443.0 million, with full-year sales down 1.6% in local currencies and 5.5% in Swiss francs to CHF 882.5 million versus 2024. The return to modest second-half growth, despite a full-year sales contraction, highlights a possible turning point in demand momentum amid currency headwinds and lingering operational...
SWX:IDIA
SWX:IDIABiotechs

Assessing Idorsia (SWX:IDIA) Valuation After Lucerastat Phase 3 Fabry Disease Results

Why the lucerastat data matters for Idorsia shares Idorsia (SWX:IDIA) just put fresh Phase 3 and long term lucerastat data for Fabry disease into the public domain, with kidney and cardiac outcomes now in focus after the study missed its primary pain endpoint. For you as a shareholder or potential investor, this shifts attention to how lucerastat might fit into Idorsia's broader rare disease pipeline, future regulatory discussions, and the perceived value of its R&D portfolio. See our latest...
SWX:SIKA
SWX:SIKAChemicals

Is It Time To Reassess Sika (SWX:SIKA) After A 30% One Year Share Price Slide?

If you have been wondering whether Sika shares are now offering value or still look expensive, this breakdown will help you put the current price into context before you commit fresh capital. Sika shares last closed at CHF149.10, with returns of an 8.7% decline over 7 days, a 6.7% decline over 30 days, an 8.9% decline year to date, and a 30.8% decline over 1 year, adding to a 39.6% decline over 3 years and a 35.0% decline over 5 years. Recent coverage around Sika has focused on its position...
SWX:NWRN
SWX:NWRNPharmaceuticals

3 European Growth Stocks With Up To 31% Insider Ownership

As European markets continue to show optimism, with the pan-European STOXX Europe 600 Index rising by 2.27% amid positive economic signals and company earnings, investors are keenly observing growth companies that demonstrate strong insider ownership. In this environment, stocks with significant insider stakes can be appealing as they often indicate confidence from those closest to the company's operations and strategy.
SWX:SOON
SWX:SOONMedical Equipment

Assessing Sonova Holding (SWX:SOON) Valuation After Recent Share Price Stabilisation

Sonova Holding (SWX:SOON) has drawn investor attention after recent performance data showed a 5.9% return over the past month, alongside a 2.2% move over the past week and a 0.1% gain in the latest session. See our latest analysis for Sonova Holding. Those recent share price gains come after a weaker patch, with the 90 day share price return at a 2.76% decline and the 1 year total shareholder return at a 28.9% loss. This suggests short term momentum is picking up while longer term holders are...